Otsuka Asks 6th Circ. For Relief From Abilify FCA Suit
Otsuka America Pharmaceutical Inc. on Friday urged the Sixth Circuit not to revive a whistleblowers' False Claims Act suit regarding off-label promotion of the antipsychotic drug Abilify against it and Bristol-Myers,...To view the full article, register now.
Already a subscriber? Click here to view full article